MXPA02009442A - Uso de la cdp-colina en el tratamento del sindrome de la abstinencia alcoholica. - Google Patents

Uso de la cdp-colina en el tratamento del sindrome de la abstinencia alcoholica.

Info

Publication number
MXPA02009442A
MXPA02009442A MXPA02009442A MXPA02009442A MXPA02009442A MX PA02009442 A MXPA02009442 A MX PA02009442A MX PA02009442 A MXPA02009442 A MX PA02009442A MX PA02009442 A MXPA02009442 A MX PA02009442A MX PA02009442 A MXPA02009442 A MX PA02009442A
Authority
MX
Mexico
Prior art keywords
acid
choline
cdp
treatment
withdrawal syndrome
Prior art date
Application number
MXPA02009442A
Other languages
English (en)
Spanish (es)
Inventor
Rafael Foguet
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of MXPA02009442A publication Critical patent/MXPA02009442A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
MXPA02009442A 2000-03-29 2001-03-28 Uso de la cdp-colina en el tratamento del sindrome de la abstinencia alcoholica. MXPA02009442A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200000765A ES2170649B1 (es) 2000-03-29 2000-03-29 Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
PCT/EP2001/003536 WO2001072288A2 (en) 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome

Publications (1)

Publication Number Publication Date
MXPA02009442A true MXPA02009442A (es) 2003-02-12

Family

ID=8492914

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009442A MXPA02009442A (es) 2000-03-29 2001-03-28 Uso de la cdp-colina en el tratamento del sindrome de la abstinencia alcoholica.

Country Status (21)

Country Link
US (1) US6894032B2 (https=)
EP (1) EP1267892B1 (https=)
JP (1) JP4724348B2 (https=)
KR (1) KR100794891B1 (https=)
AT (1) ATE281172T1 (https=)
AU (2) AU2001262141B2 (https=)
BR (1) BR0109477A (https=)
CA (1) CA2402707C (https=)
CZ (1) CZ298933B6 (https=)
DE (1) DE60106890T2 (https=)
DK (1) DK1267892T3 (https=)
ES (1) ES2170649B1 (https=)
IL (2) IL151163A0 (https=)
MX (1) MXPA02009442A (https=)
NO (1) NO329766B1 (https=)
NZ (1) NZ520825A (https=)
PL (1) PL199291B1 (https=)
PT (1) PT1267892E (https=)
RU (1) RU2251422C2 (https=)
WO (1) WO2001072288A2 (https=)
ZA (1) ZA200206349B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068104A1 (en) 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
MXPA05000451A (es) * 2002-07-11 2005-03-23 Yamasa Corp Composicion medicinal para neuropatia inducida por farmaco.
US7053064B2 (en) 2002-11-08 2006-05-30 The Mclean Hospital Corporation Compounds for the treatment of tobacco dependence and withdrawal
RU2366428C2 (ru) * 2002-12-20 2009-09-10 Дзе Маклин Хоспитал Корпорейшн Соединения для нормализации цикла сна/бодрствования
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
WO2005122767A1 (en) 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1784199A4 (en) 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
RU2072239C1 (ru) * 1991-01-11 1997-01-27 Институт биохимии СО РАМН Способ коррекции метаболической зависимости от алкоголя и средство л.е.панина для его осуществления
DE4342173A1 (de) * 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
EP0768883A4 (en) * 1994-07-01 2004-09-15 Wellstat Therapeutics Corp PYRIMIDINE NUCLEOTIDE PRECURSORS FOR THE TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS
RU2127589C1 (ru) * 1997-06-03 1999-03-20 Порембский Ярослав Олегович Способ лечения стрессорных поражений нервной системы
KR100217488B1 (ko) * 1997-06-03 1999-09-01 맹섭 골프채의 헤드커버
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Also Published As

Publication number Publication date
RU2002129579A (ru) 2004-03-27
ES2170649B1 (es) 2003-06-16
IL151163A (en) 2011-01-31
CA2402707C (en) 2007-11-13
JP4724348B2 (ja) 2011-07-13
KR20030005248A (ko) 2003-01-17
US6894032B2 (en) 2005-05-17
PL363177A1 (en) 2004-11-15
DE60106890T2 (de) 2005-11-03
NO20024574D0 (no) 2002-09-24
ES2170649A1 (es) 2002-08-01
ZA200206349B (en) 2003-08-08
IL151163A0 (en) 2003-04-10
ATE281172T1 (de) 2004-11-15
JP2003528133A (ja) 2003-09-24
DE60106890D1 (de) 2004-12-09
WO2001072288A2 (en) 2001-10-04
EP1267892A2 (en) 2003-01-02
WO2001072288A3 (en) 2002-05-10
BR0109477A (pt) 2003-06-03
AU2001262141B2 (en) 2005-03-10
CZ20023245A3 (cs) 2003-03-12
CZ298933B6 (cs) 2008-03-12
US20030162749A1 (en) 2003-08-28
EP1267892B1 (en) 2004-11-03
DK1267892T3 (da) 2005-03-07
NO20024574L (no) 2002-11-22
CA2402707A1 (en) 2001-10-04
PT1267892E (pt) 2005-03-31
KR100794891B1 (ko) 2008-01-14
NO329766B1 (no) 2010-12-13
AU6214101A (en) 2001-10-08
RU2251422C2 (ru) 2005-05-10
NZ520825A (en) 2004-04-30
PL199291B1 (pl) 2008-09-30

Similar Documents

Publication Publication Date Title
US5854238A (en) Use of a thienotriazolodiazephine to increase apolipoprotein A-I levels
DE69001493T2 (de) Verwendung von 5-methyltetrahydrofolsaeure, 5-formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe zur verwendung in der therapie depressiver stoerungen sowie die auf diese weise hergestellten arzneimittel.
DE60009697T2 (de) Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie
EP1267892B1 (en) Use of cdp-choline for the treatment of alcohol withdrawal syndrome
DE60204224T2 (de) Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
JP3942207B2 (ja) うつ性症状改善剤
ITRM20000323A1 (it) Integratore alimentare potenziante il metabolismo energetico muscolare, comprendente una alcanoil l-carnitina e ribosio.
KR100855389B1 (ko) 치매증 치료용 숙신산 유도체 에스테르의 용도
DE3873232T2 (de) Ein dideoxynukleosid enthaltendes arzneimittel.
Sethi et al. Gabapentin in geriatric mania
CN111184731A (zh) 人参皂苷Rg5在制备用于改善睡眠的药物组合物中的用途
JPH06128165A (ja) 脳機能改善剤
EP1383579B1 (en) Composition, containing carnitine and huperzin for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder
CN101461803B (zh) 葡萄内酯的用途
CN120919102A (zh) 蛋氨酸在制备用于改善精神分裂症社交障碍的药物或组合物中的用途
DE3919075A1 (de) Mittel zur behandlung von erkrankungen des zentralnervensystems und zur foerderung der cerebralen durchblutung
AU2001282510A1 (en) Composition, containing carnitine and huperzin for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder

Legal Events

Date Code Title Description
FG Grant or registration